NCT07083011View on ClinicalTrials.gov

A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions

Heart Failure With Preserved Ejection Fraction

Interventions

DRUG

68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)

68Ga-FAPI is a gallium-68 fibroblast activation protein inhibitor that will be injected into subjects during a PET (positron emission tomography) scan

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester